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ABSTRACT
Current immunoassays for interleukin-lp (IL-lp) are effective for analyzing fluids derived 
from cultured cells. However, IL-1|3 determinations in human plasma or serum samples are 
technically complicated by higher protein and lipid concentrations, physicochemical differences 
which exist between samples from healthy subjects and those experiencing acute phase responses, 
and by the fact that IL-1(3 can be produced and degraded in the blood collection tube after the 
sample is drawn, A simple chloroform extraction process has been developed which eliminates 
several of the interfering factors from plasma samples and increases the amount of IL-lp detected 
by radioimmunoassay and lymphocyte activation assay. In the radioimmunoassay, rabbit sera was 
found to influence the accuracy and variability o f  plasma measurements. Improvements in 
radioimmunoassay reagents and methods are reported which reduce this influence. Finally, 
different concentrations of IL-1|3 were measured depending on whether serum or plasma was 
tested. We propose that plasma samples collected with EDTA and aprotinin provide a better 
determination of free circulating IL-lp in vivo than serum samples, which may contain IL-lp 
secreted from blood leukocytes during the clotting process.
INTRODUCTION
Endogenous circulating factors which mediate 
host responses to infection were first 
demonstrated by passive transfer experiments 
of Atkins and Wood (1). These experiments 
showed that an endogenous pyrogen in plasma 
taken from a febrile animal caused fever when 
injected into another animal. The work of 
Kampschmidt and colleagues (2) demonstrated 
that an endogenous mediator from leukocytes 
was responsible for acute phase responses 
occurring in diverse tissues, which reinforced 
the idea that circulating systemic factors
mediated a whole-body response to infection.
It is now known that several cytokines 
(interleukin-la and p, tumor necrosis factor a, 
interferon a, and interleukin-6) are pyrogenic 
and can induce other manifestations of the acute 
phase response (3,4). Most of the information 
regarding the roles of these cytokines in 
inflammation and disease has been inferred 
from experiments in which exogenous 
cytokines were injected into laboratory animals. 
Relatively little is known about the production 
o f cytokines in vivo, their tissue distribution, 
metabolism or clearance in response to 
infection or trauma.
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Recent investigations have reported tumor 
necrosis factor (TNF) levels in serum from 
patients with parasitic infections (5), menin- 
gococcemia (6), and allograft rejection (7). In 
addition, the time course of circulating TNF in 
human volunteers' after administration of 
endotoxin has been studied (8). Measurements 
of circulating TNF have been possible because 
bioassays and immunoassays for TNF are not 
significantly inhibited by human plasma or 
serum. In contrast, plasma factors have been 
serious impediments to bioassays for interleu­
kin-1 (IL-1) (9, 10). Modified IL-1 bioassays 
o f plasma sam ples are only semiquantitative 
and laborious for large clinical studies (11-13).
The present report describes the development 
of an extraction method and modifications of 
radioimmunoassay (RIA) procedures suitable 
for measuring IL-1 p in human plasma. Several 
considerations were taken into account. For 
example, like m ost peptide hormones (14), 
IL-ip may be bound to large carrier proteins in 
the circulation. In addition, unlike the sources 
of other peptide hormones, IL-l|i-producing 
leukocytes are collected in the blood sample, 
and may secrete IL-ip in the collection tube. 
Finally, the primary sequences o f rabbit and 
human IL-1 [5 are very similar (15) and have 
common antigenic determinants (16). There­
fore, rabbit sera used in the RIA may contribute 
rabbit IL-ip or carrier proteins which interfere 
with the measurement o f human IL- lp.
METHODS 
Blood Processing,
B lood  sam ples (10 cc) from healthy 
laboratory personnel were collected in sterile, 
vacuum blood collection tubes containing 
EDTA (1.5 mg/ml of blood) (Terumo Medical, 
Elkton, MD) to which aprotinin was added 
(0.67 TIU/ml o f  blood) (Sigma, St. Louis, 
MO). The tubes were centrifuged within 10 
minutes of venipuncture (400# for 10 minutes), 
or placed on ice until centrifugation (2 hours 
maximum). The plasma was removed without 
disturbing the buffy coat, aliquoted in 1.5 ml 
microfuge tubes and spun at 10,000# at 4°C 
for 1 minute to pellet the platelets. The plasma 
was then transferred to new microfuge tubes 
and frozen at -20 °C until assay. Seven acute 
phase blood sam ples were obtained from 
Gambian patients who presented at the Medical 
Research Council clinic at Fajara with acute 
symptoms o f  malaria. All were infected with 
Plasmodium fa lciparum  and were febrile. 
These sam ples were processed in the same 
manner as those from healthy donors.
Plasma Extraction.
Because human plasma samples caused 
precipitation o f radioactivity in the RIA in 
excess o f the 100% standard in buffer (B0), a 
number o f procedures were evaluated for 
removal o f interfering plasma factors (17). 
Chloroform extraction was found to provide 
the best recovery of exogenous IL-1 p. Plasma 
(0.5 ml) and 1.0 ml o f  chloroform (Fisher 
Scientific, Fair Lawn, NJ) were added to 1.5 
ml microfuge tubes. The tubes were mounted 
horizontally on a multitube vortexer (American 
Hospital Supply, Miami, FL), agitated for 5 
minutes, transferred to a microfuge and spun 
for 5 minutes at 10,000#, 4°C. The aqueous 
phase was recovered, extracted a second time, 
then assayed.
IL-1 B Radioimmunoassay.
Initial studies employed the competitive 
inhibition assay method developed by Lisi et al. 
(18). The present assay used polyclonal rabbit 
antisera raised against a mixture of recombinant 
human IL-1 p from two sources (Cistron, Pine 
Brook, NJ, and Glaxo, Geneva Switzerland; 
the latter material was kindly provided by Dr. 
Alan Shaw). The assay buffer consisted of 
0.01 M sodium phosphate in 0.9% saline (pH 
7.4) with 0.25% bovine serum albumin (BSA, 
Sigma A-7030) and 0.25% sodium azide 
(Fisher). Reference standards ranging in 
concentration from 5,000 to 10 pg/ml were 
prepared by serial two-fold dilution of human 
recombinant IL-ip (Glaxo). Reference stan­
dards and extracted plasma samples (100 
|il/tube) were tested in 12 x 75 mm polystyrene 
tubes (Stockwell Scientific, Walnut, CA) with 
100 M.1 of diluted antiserum and 300 p.1 of 
buffer.
Five major modifications were necessary in 
order to optimize this RIA for human plasma 
samples. First, the rabbit anti-human IL-1 p 
was partially purified by precipitation with 40% 
saturated ammonium sulfate, resuspended in
0.05 M phosphate buffered saline (PBS) and 
dialyzed against PBS. This preparation was 
diluted to 5.5 |xg/ml, and 100 pi was added to 
each tube. Second, the RIA was performed as 
a sequential assay in which the initial incuba­
tion of samples and standards with rabbit anti­
human IL-ip was lengthened to 48 hours. This 
was followed by an 18 hour incubation with 
1251-iL-ip (100 (a.l/tube). Third, in addition to 
iodination by the chloramine T method (19), 
some 125I-IL -ip  lots were prepared with 
Bolton-Hunter reagent (20) (New England
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Nuclear, Boston, MA), and by a peroxidation 
method using lactoperoxidase on a solid phase 
support (Enzym obead reagent, Bio-Rad, 
Richmond, CA) as specified by the manufac­
turer's directions. All results presented were 
obtained with tracer prepared by the chloramine 
T method unless stated otherwise. Fourth, 
precipitation o f the anti-IL-ip and bound 125I- 
IL-lp was accomplished by adding 0.75 ml of  
a solution containing 1.3% sheep anti-rabbit 
IgG (Cam bridge M edical T echnology, 
Billerica, MA) and 4%  polyethylene glycol 
(16-20 kD, Sigm a), incubating at room 
temperature for 1 hour, and centrifuging at 
1000# for 30 minutes. Fifth, pooled normal 
rabbit serum (2 pl/tube), which was used in the 
original method to provide carrier proteins for 
the formation o f a large precipitate, was 
eliminated from the method optimized for 
plasma.
The radioactivity pelleted in the assay tubes 
was counted, nonspecific binding in the 
absence o f anti-IL-lp (NSB) was subtracted, 
and the result expressed as a percentage of B0 
minus NSB. The detection limit was set at 
95% binding, or at the deviation from linearity 
of the standard curve (plotted on a logistic 
probability graph) if  this occurred at a lower 
percent binding.
Plasma Chromatography.
Selected plasma samples and extracts (0.3 ml) 
were applied to 1 x 30 cm gel filtration columns 
packed with either Sephadex G-50 (Pharmacia, 
Piscataway, NJ) or Biogel A1.5m (Bio-Rad). 
The gels were equilibrated and the samples 
eluted with 0.9% saline. Fractions of 0.6 or 
1.0 ml were collected.
Lvmphocvte Activation Assays.
Thymus cells from C3H/HeJ m ice (Jackson 
Laboratories, Bar Harbor, ME) were 
suspended at a final concentration of 2.5 x 106 
cells per ml of RPMI 1640 medium supple­
mented with L-glutamine (0.3 mg/ml), 
penicillin (100 U/m l), streptomycin (100  
p.g/ml)(all from Gibco, Grand Island, NY), 10 
mM HEPES (Microbiological Associates), 2- 
mercaptoethanol (Eastman Kodak, Rochester, 
NY) and 2.5% heat-inactivated fetal bovine 
serum (Hyclone, Logan UT). The cells were 
incubated with 1 ng/ml phytohemagglutinin 
(PHA)(Difco, Detroit, MI) and either plasma 
fractions or various concentrations of human 
IL-ip in 96 well microtiter plates at 37 °C, 5%
CO2. The rates o f proliferation were assessed 
by adding 1 ¿iCi ° f  3H-thymidine (6.7 
Ci/mmol, New England Nuclear) to each well 
after 48 hours, then harvesting the cells and 
counting incorporated radioactivity at 72 hours. 
A subclone (D10S) of the murine T-helper cells 
D10.G4.1 (21) was also employed in similar 
assays except these cells were plated at a lower 
density (4 x 105 cells per ml) and cultured 
without PHA.
Individual plasma samples (7 ml) from four 
subjects were mixed with 0.5 ml of anti-IL-1 
bound to Sepharose 4B (Pharmacia) in 15 ml 
tubes which were rotated end over end at 37 °C 
for 4 hours. The Sepharose-bound IL-1 
preparation was a mixture of 3 different 
Sepharose/antibody conjugates, directed 
against recombinant human IL-la, IL-lp and 
monocyte-derived IL-1. Controls were 
prepared by mixing plasma with Sepharose- 
bound human serum albumin. The optical 
density (280 nm) of the plasma was measured 
before and after incubation with the Sepharose 
conjugates to determine the dilution due to 
mixing.
Data Analysis.
Data are presented as mean ± standard error. 
Samples below detection were assigned IL-lp 
concentrations equal to the detection limit of the 
assay. Statistical significance was determined 
by appropriate nonparametric tests for paired or 
multiple groups using Stat-View software 
(Abacus Concepts, Inc., Calabasas, CA) on a 
Macintosh computer (Apple Computer, Inc., 
Cupertino, CA).
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RESULTS 
Effect of Extraction on Normal Plasma.
After agitating and centrifuging the mixture of 
plasma and chloroform, an upper aqueous layer 
which contained IL-1 (3, and a lower chloro - 
form layer which often contained some pigment 
from the plasma sample was observed. A 
white, 1 mm thick precipitate separated the two 
phases. Extracting the aqueous phase a second 
time increased the IL-ip immunoreactivity by 
approximately 35%, but a third extraction 
yielded no further increase (data not shown).
To determine if the aqueous phase retained 
IL-1 biological activity, unextracted and 
extracted plasma samples from normal subjects 
were chromatographed with Sephadex G-50 
and each fraction tested for lymphocyte 
activation (Figure 1A). Unextracted plasma 
exhibited a characteristic pattern of suppressive 
activity eluting at the void volume, as previous­
ly described (12). Extracted plasma applied to 
the G-50 column exhibited less inhibitory 
activity and more IL-1 -like stimulatory activity. 
This stimulatory activity was neutralized by 
adding a mixture of rabbit anti-human IL-1 ct 
and anti-human IL-1 [3 (each at 0.5% by 
volume) to each fraction and incubating at22°C 
for 2 hours before assay (Figure IB).
The high molecular weight plasma constit­
uents were resolved by chromatography with 
Biogel A 1,5m (1,5 x 106 dalton exclusion 
limit). W hole plasma was applied to the 
column and each fraction divided into two 
portions. One portion was further divided in 
three for measuring optical density, bioactivity 
and immunoreactivity without extraction. The 
ocher portion was extracted and then divided 
for measurements o f optical density and im- 
nuinoreactivity. The optical density measure­
ments indicated that the extraction process 
removed proteins in the 300 to 800 kD range 
(Figure 2A). Endogenous bioactivity eluted at 
>700, 600-200, 17 and <2 kD (Figure 2B). 
Immunoreactivity was observed in unextracted 
fractions eluting at 17 kD (Figure 2C). After 
extraction, immunoreactivity was also observed 
in >700 and 600-200 kD fractions.
A ûttom .£uritt.aD dA ssny-Y iuiabiltot
Extracted plasma samples retested in con­
secutive assays exhibited a coefficient of 
variation of 109% when w hole rabbit 
anti-human IL -1 fi was used (Figure 3). The 
coefficient o f variation using ammonium sulfate 
precipitated IL-1 fi was 16%.
Fraction Number
F ig u re  1 . Plasma chrom atography with Sephadex 
G-50. A . Whole (open circles) or extracted plasma 
(solid circles) fro m  3 donors were each chromato­
graphed, then individual fra c tio n s were assayed fo r  
lym p h o cy te  a c tiv a tio n  on m u rin e  thym ocytes. 
Biological activity is expressed as a stimulation index 
calculated as sam ple-induced proliferation divided by 
basal proliferation. The effect o f  10 pglm l recombinant 
human IL-1 j) (G laxo) in the thymocyte assay was a 
stim ula tion  index o f  1 .5; 100 p g lm l induced  a 
stim ulation  index o f  2.5. B . E xtracted  plasma  
frac tions (one blood donor) were tested with either a 
mixture o f  0.5% rabbit anti-human I L - l a  and 0.5%  
rabbit anti-human I L - ip  (solid circles), or with 1% 
normal rabbit serum (open circles).
Immunoreactivity of Absorbed Plasma.
To verify that the immunoreactivity detected in 
plasma by RIA was due to competition between 
the tracer and native IL-1|3 in the plasma, four 
plasma samples were absorbed with anti-IL-1 
bound to Sepharose, then extracted and tested 
in the RIA. The absorbed plasma did not 
exhibit any competition with 125I-IL-lp in the 
radioimmunoassay (99 ±  2 % binding, Figure 
4). Portions of the plasma which had not been 
absorbed exhibited 87 ±  1 % binding. 
Incubation of extracted plasm a with 
albumin/Sepharose showed only a slight 
change in binding which was attributable to the 
dilutional effect o f adding the Sepharose 
suspension to the plasma.
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F igure 3. Influence o f  antiserum on assay variability. 
Retests are expressed as percent o f  initial measurement.
Effect o f Plasma and Extraction on ths 
Standard Curve,
Serial two-fold dilutions o f  recombinant 
human IL-1 p were prepared in the assay buffer 
and in EDTA/aprotinin-treated plasma, which 
had been absorbed with rabbit anti-human 
IL-lp bound to Sepharose 4B. The plasma 
was then extracted twice and each set o f  
dilutions assayed. The standard curves were 
virtually indistinguishable over a concentration 
range of 80 pg/ml to 5 ng/ml (Figure 5), 
indicating that the chloroform extraction did not 
affect the immunoreactivity of the IL-lp, and 
that the extracted plasma, EDTA and aprotinin 
did not alter the standard curve.
Elution Volume [mi]
F ig u re  2 . B iogel A 1,5m  chromatography o f whole 
plasm a fro m  one individual. A . Optical density o f  one 
p ortion  o f  each frac tion  w as measured directly after 
elu tion  fro m  the colum n (solid  circles), the other 
portion was extracted, then measured (open circles). B. 
The bioactivity  o f  unextracted plasma fractions was 
m easured with D IOS cells. Human recombinant IL-1 fi 
(10 pg /m l) induced a stim ulation index o f  3.0. C. 
Im m unoreactiv ity o f  unextracted (solid circles) and 
extracted fractions (open circles).
F igure 4. Immunoabsorption o f  plasma. Samples 
were extracted and added directly to the RIA (undiluted), 
preincubated with anti-IL-1 /Sepharose, then extracted 
and assayed. A s controls, other portions o f  the plasma 
samples were preincubated with albumin bound to 
Sepharose or after diluting the plasma to the extent 
which occurred when preincubating with the Sepharose.
OO
IL -lp  [pgAnl]
Figure 5. Four standard curves were prepared by 
serial dilutions in standard assay buffer (solid line, n -  
4) or in plasma previously absorbed with anti-IL-1 
(dashed line, n = 4).
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Table 1 Whole anüserum + NRS
Amm. Sulf, Ppt. 
+ NRS
Amm. Sulf, Ppt.
no NRS
Bo 18 ±0,5 23 ±0.6 22 ± 1.5
NSB 3 ±0,2 3.1 ± 0.1 3.1 ±0.1
ED-50 1,7 ±  0.1 2.6 ±0.3 0.5 ± 0.1
Detection Limit 141 ±49 8&± 16 45 ± 6
Radioimmunoassay param eters at different stages o f 
assay development (data from  3-5 assays each) B 0 and 
NSB are expressed as percen t o f  total counts o f  
radioactivity added p e r  assay tube. Fifty percent 
binding (ED-50) is expressed in nglm l and detection 
limit is expressed in pglml.
Alternative Iodination Methods.
The Enzymobead tracer preparation bound 
poorly (<10%) at the antibody dilutions used in 
these assays. These results, along with 
previous data that peroxidation destroyed the 
biological activity o f  IL-1 (22) led us to 
abandon this method.
Assays performed with tracer freshly 
prepared with Bolton-Hunter reagent exhibited 
standard curves with greater sensitivity (32 ±  7 
pg/ml), but reduced binding (15 ± 1.6%), 
compared to the chloramine T tracer (Table 1). 
The sensitivity declined over several weeks, 
however, due to breakdown o f the tracer. 
Removing free i25I by chromatography 
restored the sensitivity.
Influence of Blood Processing.
Six blood samples were drawn into empty, 
sterile polypropylene syringes and each sample 
was immediately distributed into three vacuum 
blood collection tubes, one containing EDTA 
and aprotinin, the second containing heparin, 
and the third containing no anticoagulant. 
Platelets were removed from the EDTA/apro- 
tinin-treated plasma, but not the heparinized 
plasma. The IL-1 (3 concentrations measured in 
the heparinized samples were within 11 ± 10% 
of the levels measured in the EDTA/aprotinin 
samples (Figure 6). The IL-ip concentrations 
measured in serum samples were significantly 
higher (75 ±  36%) than corresponding 
EDTA/aprodnin samples.
Altered Binding in Normal Rabbit Serum.
At this stage of assay development, IL-l[i 
immunoreactivity measured in plasma from 
healthy subjects averaged >200 pg/ml. From 
cloning and expressing rabbit IL-1 (15), we 
had found that recombinant rabbit IL-1J3 
cross-reacted with rabbit anti-human IL-lp
We becam e concerned about undesired 
interactions between human plasm a and the 
pooled normal rabbit serum which was added 
to the assay to enhance precipitation of the 
primary-secondary antibody com plex. The 
precipitation procedure was re-optim ized as 
described in the methods in order to achieve 
effective precipitation without normal rabbit 
serum in the assay buffer. The effect o f  these 
changes on assay parameters is presented in 
Table 1. Plasma IL-1(3 immunoreactivity in 
normal human plasm a w as sign ificantly  
reduced from 212 ±  13 pg/ml to 62 ±  4  pg/ml 
in the absence o f normal rabbit serum (Figure 
7).
F igure 6. The influence o f  blood p rocess ing  on IL-1 ¡3 
levels. The IL-1 ¡3 concentrations m easured fo r  each o f  6  
blood samples v/ere norm alized to the value m easured in 
the EDTAIaprotinin-treated sample (=100%).
F ig u r e  7. In fluence  o f  norm al ra b b it serum  on 
immunoreactivity. A liquots o f  plasm a sam ples were 
tested in parallel assays using norm al rabb it serum  
(NRS) to enhance antibody precip ita tion  a n d  assays 
optimized to recover antibody!tracer w ithout NRS.
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F ig u re  8. D ilution o f  immunoreactivity. Extracted  
p lasm a  samples were diluted with buffer, then assayed. 
The results are expressed as a percentage o f  the IL-1 /? 
concentration measured in the undiluted plasma. A t a 
1:3  dilution, all samples were below the detection limit 
o f  the assay. The dashed, diagonal line represents ideal 
dilution behavior.
D ilution of Endogenous Immunoreactivity.
Seven  plasma sam ples (mean IL-1J3 
concentration: 186 ±  26 pg/ml) were diluted 
1:1.5 and 1:3. The mean IL-ip concentration 
in the samples diluted 1:1.5 was 127 ±  18 
(68%, Figure 8), and at a 1:3 dilution, all were 
below 78 pg/ml.
Recovery of Exogenous Natural IL-lB.
In 3 separate assays, 10 p.1 of natural IL-1 
(Genzyme, Boston, MA) was added to 0.3 ml 
plasma samples (final intended concentration: 
250-330 pg/ml), incubated for 1 hour at 22°C, 
then extracted. Endogenous IL-1 ¡3 measured in 
unspiked samples was subtracted from the 
levels found in the spiked samples and the dif­
ference divided by the measured value for the 
spike in buffer (% recovery). For 9 plasma 
samples tested, recovery was 71 ± 3 %.
Fasting and Postprandial Plasma IL-lB Levels.
Blood was sampled from seven subjects in the 
morning after an overnight fast. Plasma IL-1 (3 
levels in these samples were 63 ± 6 pg/ml. The 
subjects then ate breakfast (orange juice, coffee 
and pastries) and additional blood samples 
were collected 90 minutes later. In these 
samples, the IL-1(3 levels were essentially 
unchanged at 58 ± 3 pg/ml. Therefore, simple 
interventions such as a light meal or a previous
venipuncture do not appear to significantly 
affect plasma IL-ip levels.
Effect o f  Extraction on Acute Phase Plasma.
In contrast to unextracted plasma from healthy 
subjects, which usually exhibits >100% 
binding in the RIA, several plasma samples 
from malaria patients exhibited very low 
percent binding (Figure 9). The 60% and 1 % 
binding of the two extreme samples correspond 
to immunoreactive IL-1J3 levels of 700 pg/ml 
and >10,000 pg/ml, respectively. Extracting 
the plasma eliminated the apparent high levels 
of IL-ip . This anomalous effect of extraction 
and the unexpected magnitude of the IL-ip 
levels in unextracted plasma were ultimately 
explained upon examination of the centrifuged 
and decanted test tubes which had contained the 
unextracted plasma samples. These tubes 
retained little primary/secondary antibody 
precipitate whereas the tubes used to measure 
the extracted plasma samples contained 
well-formed, adherent pellets. Assays were 
repeated on the unextracted acute phase plasma, 
and the tubes examined after the secondary 
antiserum and polyethylene glycol solution was 
added and the tubes were centrifuged, but 
before the supernatant was decanted. 
Precipitate was suspended in the aqueous 
phase. Centrifugation for an additional 45 
minutes at 1500,? failed to pellet the precipitate 
in the tube. Therefore, the high levels of 
apparent immunoreactivity (i.e., reduced 
radioactivity in the test tubes) observed in some 
unextracted plasma samples of malaria patients 
did not result from competition between plasma 
IL-lp and 125I-IL-1|3 for binding with rabbit 
anti-human IL-ip, but rather, from incomplete 
precipitation o f antibody/antigen complexes.
Normal Acute Phase
Figure 9. Influence o f  extraction on normal and acute 
phase plasma.
463
DISCUSSION
This investigation sought to develop a 
practical method for measuring IL-lp in human 
plasma. The presence o f  interfering and 
inhibiting substances in human plasma required 
the adoption o f  an extraction process. In a 
1973 review (23), Chard listed useful criteria 
for validating extraction o f  peptide hormones 
for radioim m unoassay. First, the method 
should be fast and sim p le. Chloroform  
extraction o f a large number o f samples can be 
accomplished in less than 30 minutes. Second, 
the hormone should be concentrated into a 
smaller volum e to im prove sensitivity. The 
chloroform  extraction  precipitates high 
molecular weight proteins which reduces the 
sample volume about 20% , but leaves the IL-lp 
in solution, Third, the procedure should not 
concentrate n o n -s p e c if ic  inhibitors or 
proteolytic e n z y m e s . T h e chloroform  
extraction apparently rem oves a considerable 
amount of the m aterial which inhibits the 
biological assay (Figure 1 A). Fourth, recovery 
should be greater than 50% . Recovery of 
natural, monocyte-derived IL-1 p was 71 ± 3 %. 
W e tested recovery w ith  natural IL-1, rather 
than recombinant, in case the natural molecule 
was altered by post-translational processing 
(24) which might render it more susceptible to 
degradation by the ch loroform  extraction. 
Fifth, the im m unoreactivity o f  the extract 
should dilute in parallel to the standard curves. 
The IL-lp immunoreactivity in extracted plasma 
was within 4 ±  10 % o f  ideal dilution. Sixth, 
extraction materials should be readily available 
and not vary from  batch to batch. Chloroform 
m eets these criteria. Seventh, the extract 
should be physicochemically similar to the pure 
hormone, The majority o f  the immunoreactive 
IL -lp  eluted from gel filtration columns at 17 
kD, the molecular weight o f  the mature form of 
IL-lp. Eighth, the amount o f  extracted protein 
m easured should  ch an ge in response to 
appropriate physiological circumstances. This 
criterion is the subject o f  a separate report (25).
The use o f serum  w as rejected a priori 
because leukocytes w hich produce cytokines 
are in the blood sam ple and may continue to 
synthesize and secrete cytokines during clotting. 
In fact, the clotting p rocess itse lf may be a 
stim ulus for cytokine production and release
(26). This is particularly worrisome when 
serum is obtained from patients with circulating 
activated leukocytes, T h is possibility was 
supported by m easurem ents o f  plasma and 
serum derived from  the sam e blood samples 
w hich showed 75%  higher levels o f IL-1 p in 
the serum than the plasm a (Figure 6). Heparin 
m ay interfere with antigen-antibody binding
(27), therefore EDTA, which has the additional 
benefit o f  inhibiting calcium -dependent 
proteases, was the preferred anticoagulant. 
The influence o f proteases was further reduced 
by adding the protease inhibitor aprotinin, and 
remqving platelets which release proteolytic 
enzymes when ruptured by a freeze-thaw cycle.
Plasma from several donors (in addition to 
the individual data in Figure 2) has been 
chromatographed with B iogel A1.5m . Im­
munoreactivity in unextracted fractions was 
usually found at 17 kD and sometimes at lower 
molecular weights. After extraction, the 
fractions at the void volume often exhibited  
im m unoreactivity, and fractions eluting  
between 600 and 200 kD sometimes exhibited 
immunoreactivity. The 17 kD peak was not 
significantly affected by extraction^but the <2 
kD material was often destroyed, th e  >700 kD 
immunoreactivity revealed by extraction may 
represent bound IL-lp which is released from 
large proteins denatured by chloroform. One 
candidate is c^macroglobulin (725,000 kD), 
which has been proposed to be an IL-1 binding 
protein (28). The immunoreactivity found in 
the 600 to 200 kD fractions after extraction may 
also be released from larger protein carriers: in 
one experiment (data not shown) the 600 to 
200 kD extracts were pooled and reapplied to a 
Biogel column, the immunoreactivity then 
eluted in a peak around 17 kD.
A ssay reproducibility  was m arkedly  
improved by using rabbit anti-human IL -lp  
precipitated by ammonium sulfate, rather than 
whole antiserum. The dilution o f the whole 
antiserum in the RIA (1:6,000) may have 
resulted in insufficient dilution of other factors 
in the rabbit serum which caused interference in 
the presence o f human plasma.
The levels o f  IL-1 estimated in fractionated 
normal plasma tested in bioassay were in the 10 
to 100 pg/ml range (Figures 1A and 2B). 
When normal rabbit serum was included in the 
RIA, immunoreactive IL -lp  levels averaged 
212 ±  13 pg/ml, however, eliminating the 
normal rabbit serum brought the immunoreac­
tive IL-lp measurements more in line with the 
bioassay results. Series e ta l. (29) detected 0.3 
to 6 pg/ml of IL-1 activity in the post-operative 
plasma o f surgical patients which had been 
extracted with silica and measured in a two 
stage cell line bioassay. The recovery of 
exogenous IL-1 from the plasma by this 
method was rather low, 30 to 40% and levels 
in healthy subjects were not reported. In 
contrast, Reuter et al, (30) found in excess of 
400 pg/m l o f IL -lp  immunoreactivity in 
unextracted samples. These high levels may be 
due to testing serum rather than plasma.
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Whether normal rabbit serum was used in the 
assay was not specified.
Although the number o f  plasma samples 
tested from patients with malaria were insuf­
ficient to characterize the role o f IL-1 in this 
disease, these samples have demonstrated that 
unextracted plasma from patients with severe 
infections cannot be expected to behave in the 
RIA in a manner similar to plasma from healthy 
subjects. The fact that some o f the malarial 
samples contained factors which interfered with 
the precipitation of the antibody/tracer complex 
is consistent with the changes known to occur 
in plasma during the acute phase response. 
Several proteins, including lipoproteins such as 
serum am yloid A, can increase over one 
thousand-fold. Free fatty acid concentrations 
are markedly elevated as well. Such factors 
could influence precipitation by changing the 
v iscosity  o f  the solution ox interfering with 
hydrophobic interactions between proteins, 
including inter- actions during anttgen-antibody 
association. The ability of chloroform to 
separate lipids from solution may account for 
the removal of the interference by extraction. 
T h ese findings strongly suggest that im- 
munoreactive IL -ip  found in plasma samples 
from different pathological conditions should 
be verified through immunoabsorption, dilution 
and bioactivity experiments.
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